



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Nanrilkefusp alfa

Chemical Properties

CAS No. : 1416390-27-6

Formula:

Molecular Weight:

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Nanrilkefusp alfa (SO-C101; SOT101), a fusion protein, serves as a powerful and selective agonist of the IL-15 and IL-15R α sushi + domain. It promotes the proliferation and activation of memory CD8 + T cells, natural killer (NK) cells, γ/δ T cells, and NKT cells to inhibit tumor growth. Nanrilkefusp alfa demonstrates remarkable anti-metastatic effects in melanoma and effectively suppresses tumor progression in various mouse tumor models [1] [2].
In vitro	Nanrilkefusp alfa, at concentrations ranging from 0.01 to 10 nM over 7 days, expands and activates NK cell subtypes from human PBMCs in vitro. At 1 nM for 20 hours, it induces cytotoxic and tumor cell-killing activity in human NK cell subtypes. Additionally, at 0.1, 1, and 10 nM for both 3-day and 7-day durations, it stimulates the expression of cytotoxic receptors NKp30, DNAM-1, and NKG2D on human NK cells [1].
In vivo	Nanrilkefusp alfa administered subcutaneously at 2 mg/kg for 4 consecutive days over 2 weeks reduces tumor development and growth in the metastatic kidney cancer Renca mouse model, dependent on natural killer (NK) and CD8+ T cells. It also activates NK and CD8+ T cytotoxicity genes in the TC-1 tumor model. In the TRAMP-C2 tumor mouse model, intraperitoneal administration of Nanrilkefusp alfa at 1 mg/kg, with or without 12.5 mg/kg anti-PD-1, for 4 consecutive days over 2 weeks, reduces established tumor growth and expands CD8+ T cell and NK cell populations while sparing T regulatory cells (Tregs). The compound mediates inhibition of TRAMP-C2 tumor development, primarily relying on NK and CD8+ T cells. In both models, Nanrilkefusp alfa demonstrates effectiveness in activating immune cells and reducing tumor growth.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481